Boston Scientific upgraded at BofA/Merrill As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
News For BSX From The Last 14 Days
Check below for free stories on BSX the last two weeks.